Company Overview and News

2
Miners push ASX higher as aged care stocks fall

2018-09-21 theage.com.au
The Australian sharemarket has closed the week higher as the US finally imposed additional tariffs against China, bringing an end to weeks of uncertainty.
PLS AOG PILBF RIO BLT RIO LYSCF BHPBF IGO IIDDY REG RTPPF BHP RIO LYSDY RTNTF BBL BHP BHPLF WNARF JRHHY EHE JHC WSA

2
Miners push ASX higher as aged care stocks fall

2018-09-21 smh.com.au
The Australian sharemarket has closed the week higher as the US finally imposed additional tariffs against China, bringing an end to weeks of uncertainty.
PLS AOG PILBF RIO BLT RIO LYSCF BHPBF IGO IIDDY REG RTPPF BHP RIO LYSDY RTNTF BBL BHP BHPLF WNARF JRHHY EHE JHC WSA

 
Trade tariffs hit ASX as resource stocks fall

2018-09-18 theage.com.au
Australian shares closed the session lower on Tuesday as the announcement on further tariffs on China hit major materials and energy stocks.
WOPEF BLT SGQ OGFGY REG RSG BEPTF GALXF RMGGF WNARF WSA AOG BHPBF WTCHF WPL BCHEY WOPEY BPT GXY RMGGY BHP BBL BHP OGFGF BHPLF JRHHY EHE JHC ORG

 
Trade tariffs hit ASX as resource stocks fall

2018-09-18 smh.com.au
Australian shares closed the session lower on Tuesday as the announcement on further tariffs on China hit major materials and energy stocks.
WOPEF BLT SGQ OGFGY REG RSG BEPTF GALXF RMGGF WNARF WSA AOG BHPBF WTCHF WPL BCHEY WOPEY BPT GXY RMGGY BHP BBL BHP OGFGF BHPLF JRHHY EHE JHC ORG

 
UPDATE 1-Australian aged-care stocks plunge as powerful inquiry looms

2018-09-17 reuters
SYDNEY, Sept 17 (Reuters) - Shares in Australia’s largest listed aged-care operators plunged to record lows on Monday after the government said it would set up a powerful public inquiry to investigate abuse and mistreatment in the sector.
AOG JRHHY EHE JHC REG

 
Aged care has 'not kept pace': Providers welcome inquiry

2018-09-16 theage.com.au
Australia's biggest aged care companies are calling on the royal commission into the $20 billion sector to provide clarity on how businesses and service providers can keep pace with burgeoning demand as the population ages.
AOG AYU JRHHY JHC

 
Aged care has 'not kept pace': Providers welcome inquiry

2018-09-16 smh.com.au
Australia's biggest aged care companies are calling on the royal commission into the $20 billion sector to provide clarity on how businesses and service providers can keep pace with burgeoning demand as the population ages.
AOG AYU JRHHY JHC

 
Aveo boosts FY profit as unit sales lift

2018-08-15 perthnow.com.au
Aged accommodation provider Aveo Group has lifted full-year profits 44 per cent as a major property sale and asset revaluations boosted earnings from new unit sales.
AOG

 
Ex-funeral boss won't have his coffin lined with Invocare shares

2018-06-07 theage.com.au
Richard Davis, the former chief executive of funeral service operator Invocare, is well aware of that.
AOG

 
Ex-funeral boss won't have his coffin lined with Invocare shares

2018-06-07 smh.com.au
Richard Davis, the former chief executive of funeral service operator Invocare, is well aware of that.
AOG

 
Aveo executive resigns after being identified as 'poo jogger'

2018-06-07 theage.com.au
Just days after criminal charges were laid against ANZ Group and two investment banks, Aveo Group’s national quality manager, Andrew Macintosh, resigned after being identified as Brisbane’s notorious poo jogger.
AOG

 
Aveo executive resigns after being identified as 'poo jogger'

2018-06-07 smh.com.au
Just days after criminal charges were laid against ANZ Group and two investment banks, Aveo Group’s national quality manager, Andrew Macintosh, resigned after being identified as Brisbane’s notorious poo jogger.
AOG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AOG / AVEO GROUP on message board site Silicon Investor.

Alberta Oil u0026 Gas (AOG-ASE) Alberta Oil u0026 Gas (AOG-ASE) Alberta Oil u0026 Gas (AOG-ASE)